Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855162 | 0.85 | PIK3CD (0.40) | RXFP1MAPK1HTTPDE4BLMNA | |
| SCHEMBL4852894 | 0.82 | NOTUM (0.39) | RXFP1GRM5MAPK1PDE4BLMNA | |
| SCHEMBL4850875 | 0.81 | MAPT (0.38) | RXFP1GRM5PDE4BLMNAMAPT | |
| SCHEMBL14158805 | 0.81 | MAPK1 (0.46) | MAPK1HTTLMNAMAPTTDP1 | |
| SCHEMBL4848229 | 0.80 | MAPT (0.34) | RXFP1GRM5MAPK1HTTPDE4B | |
| SCHEMBL14158831 | 0.78 | MAPT (0.55) | RXFP1MAPK10LMNAMAPT | |
| SCHEMBL14280497 | 0.78 | MAPT (0.34) | RXFP1GRM5MAPK1HTTPDE4B | |
| SCHEMBL4856292 | 0.74 | MAPT (0.38) | RXFP1MAPK1LMNAMAPT | |
| SCHEMBL14158830 | 0.71 | KDM4E (0.42) | MAPK10LMNAMAPT | |
| SCHEMBL4855863 | 0.68 | RXFP1 (0.36) | RXFP1MAPK1HTTPDE4BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | RXFP1 3822/4885GRM5 3372/4885MAPK1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.